Drawing for Serial No. 87417104

USPTO serial 87417104

Serial No. 87417104

Reviewed by CopyMark Law Group

Reg. 5451145Status 701Registered
Filing date
Status date
Registration date
Apr 24, 2018
Examiner
SEVERSON, KAREN
Law office
Historical data usage

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with Serial No. 87417104?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kisuk Lee

Kisuk Lee Harness, Dickey & Pierce, PLC7700 Bonhomme Avenue, Suite 400Saint Louis, MO 63105United States

Goods and services

ClassDescriptionStatusFirst use
005Vaccines; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organ; agents affecting peripheral nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the peripheral nervous system; agents for immunity adjustment, namely, pharmaceutical preparations for the prevention and treatment of disorders of the immune system; biological preparations for medical purposes; amino acids for medical purposes; antibiotic preparations; agents for respiratory organs, namely, pharmaceutical preparations for the prevention and treatment of disorders of respiratory organs; chemotherapeutics; reagents for measuring Hepatitis B Surface antibody, namely, medical diagnostic reagents for detecting Hepatitis B surface antibody; diagnostic preparations for medical use; AIDS, acquired immune deficiency syndrome diagnostic agents, namely, diagnostic preparation for medical use; AIDS, acquired immune deficiency syndrome vaccines; agents affecting central nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the nervous system; veterinary vaccines; agents for tumor treatment, namely, pharmaceutical preparations for the treatment of tumor; agents for urogenital organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of urogenital organs; kits for protein test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a protein related to a disease; kits for gene test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a gene related to a disease; biopharmaceuticals for the treatment and prevention of infectious diseases, tumor- related diseases, auto-immune diseases, hormone- deficiency diseases; biopharmaceutical preparations, namely, polypeptides, proteins, monoclonal antibodies, hormones for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone deficiency diseases; biotherapeutic preparations and substances for medical purposes for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases; biotechnological preparations for medical purposes for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases; pharmaceuticals for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases, tuberculosis, HIV/AIDS, neurological disorders, urge incontinence, neurogenic detrusor overactivity; chemical preparations for pharmaceutical purposes, namely, chemical reagents for medical purposes; chemico-pharmaceutical preparations for the treatment of tuberculosis, HIV/AIDS, neurological disorders, urge incontinence, neurogenic detrusor overactivityACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 13, 2024NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Dec 13, 20248.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Dec 13, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 28, 2024ES8RTEAS SECTION 8 RECEIVED—
Apr 24, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 26, 2021ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 24, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 6, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 6, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 17, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 28, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 7, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 7, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 7, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 14, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 14, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 14, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2017DMCCDATA MODIFICATION COMPLETED—
Jun 12, 2017ALIEASSIGNED TO LIE—
Jun 8, 2017DOCKASSIGNED TO EXAMINER—
Apr 26, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 25, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 22, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance